Merck Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
Links shared publicly online about this topic.
- 451total visits
Merck Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application
View full resource at drugs.com
Tags: Multiple Sclerosis, Drug, Clinical Trial, FDA, Merck & Co., News
Most Recently Shared on March 9, 2011 at 10:17 pm By:
Merck Receives Complete Response Letter From FDA on Cladribine Tablets New Drug Application: DARMSTADT, Ge... http://bit.ly/fzXQnq #drug
EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis
news-medical.net — “EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on the new drug application (NDA) for Cladribine Tablets, EMD Serono's proprietary investigational oral formulation of cladribine, as a therapy for relapsing-remitting multiple sclerosis (MS).” View full resource at news-medical.net
Most Recently Shared on March 2, 2011 at 10:55 am By:
News-Medical.Net Health News and Oncology
Oncology News: EMD Serono receives FDA CRL on Cladribine Tablets NDA for relapsing-remitting multiple sclerosis:... http://bit.ly/eokKUi
Advertisement
